Forum Replies Created

  • Duduzile Nsibande

    Member
    September 12, 2020 at 7:19 am in reply to: Where do you draw the line between inducement and engagement?

    I don’t think there is a clear line that can be drawn relating to undue undue inducement. Even where IRBs have standard and appropriate amounts of reimbursements, what could be considered ordinarily reasonable compensation for one group of participants can be seen as ‘undue influence to participate’ for very poor and vulnerable participants within the same study. This form of inducement may also occur in high-risk clinical trials that offer drugs or health care that is not available in public health care settings.

  • Duduzile Nsibande

    Member
    August 7, 2020 at 7:56 am in reply to: Engaging faith-based stakeholders about the HIV prevention package

    I think it may help to arrange a meeting with some of the organizations leaders to create a platform where you can listen to their issues. this might create an opportunity for you to present figures on the impact of non-condom use.

  • Duduzile Nsibande

    Member
    July 29, 2020 at 5:43 pm in reply to: Stakeholder engagement for HIV Vaccine development

    I think discomforts are around understanding vaccine-induced sero-reactivity which may result in being labelled as HIV positive, unless one has disclosed participating in a vaccine trial.communities also get concerned about how long the antibodies will persist post-trial participation leading to distress about insurance claims/payouts.